Print

Lentigen Corporation Announces Relocation to New Facility  
9/9/2008 9:33:04 AM

GAITHERSBURG, Md., Sept. 9 /PRNewswire/ -- Lentigen Corporation announced today that it has relocated its corporate headquarters, research labs and manufacturing from the University of Maryland Baltimore County TechCenter, to 910 Clopper Road, Suite 200 South Building, Gaithersburg, MD 20878 (Tel: 301.527.4200).

Located along Maryland's I-270 technology corridor, the almost 26,000 square-foot facility will accommodate Lentigen's future growth needs as the leading developer and manufacturer of lentiviral vectors (LVs) and proteins for a wide range of clinical and research applications. Two self-contained suites measuring 4,900 square feet will allow the simultaneous production of both LVs and proteins in compliance with FDA-regulated current good manufacturing practices (cGMP).

"We appreciated the opportunity afforded to grow our company at the TechCenter, but the move to our new facility is a significant step forward in our evolution as a biotech company," stated Tim Ravenscroft, Lentigen's CEO. "The new facility provides an opportunity to expand our research programs. More importantly, the addition of the cGMP manufacturing suites will allow us to manage our programs from the labs through manufacturing to the clinic. We plan to manufacture lentiviral products for clinical trials during 2009 and we will have capacity to handle manufacturing projects for collaborators as the market for lentiviral products expands."

About Lentigen Corporation

Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vector technology for a wide range of therapeutic, vaccine, and research applications in biotechnology and medicine. Lentiviral vectors are the most efficient vehicles for the delivery of genes or gene silencing sequences stably into cells. Lentigen is a highly collaborative company, co-developing lentiviral vector-based products across a broad spectrum of bench to clinical applications. Partnerships include The National Institutes of Health, The University of Pennsylvania, Invitrogen, ThermoFisher Scientific and The U.S. Army. For further information, visit www.lentigen.com

CONTACT: Investors - Cecelia Heer, cheer@rlcinc.com, or Media - Megan
Dubrowski, mdubrowski@rlcinc.com, both of Richard Lewis Communications,
Inc., +1-212-827-0020, for Lentigen Corporation

Web site: http://www.lentigen.com/


//-->